The value of the Left Ventricular Emission Fraction in Patients with Ischaemic Heart Disease with Diabetes Mellitus 2 in the Assessment of the Effectiveness of Sitagliptin/Metformin

The appointment of a DPP 4 inhibitor in patients with СAD and DM 2 with moderate ejection fraction (HFmrEF) continues to be studied. Analysis of glycemic parameters in patients with CAD, with DM 2, depending on the phenotype of HF when taking sitagliptin/metformin (S/M). We examined 50 patients with...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2021-12, Vol.242, p.155-155
Main Authors: Trigulova, Alimova, D.A., Tashkenbaeva, N.F., Bekmetova, F.M., Ilkhamova, L.T., Akhmedova, Sh.S., Shek, A.B.
Format: Article
Language:English
Subjects:
Antidiabetics
Blood glucose
Cardiovascular disease
Cardiovascular diseases
Chi-square test
Coronary artery disease
Diabetes
Diabetes mellitus
Echocardiography
Epidermal growth factor receptors
Fasting
Heart diseases
Hemodynamics
Ischemia
Metformin
Parameters
Patients
Phenotypes
Stenosis
Ventricle
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The appointment of a DPP 4 inhibitor in patients with СAD and DM 2 with moderate ejection fraction (HFmrEF) continues to be studied. Analysis of glycemic parameters in patients with CAD, with DM 2, depending on the phenotype of HF when taking sitagliptin/metformin (S/M). We examined 50 patients with CAD with DM 2 at the age of 62.8±1.29 years. Determined fasting glycemia (FG), postprandial (PPG), HbA1c, Echocardiography. Compiled by groups with HFpEF n-33, HFmrEF n-17. Treatment regimen: basic therapy for CAD, S/M). Follow-up for 48 weeks. In patients with HFmrEF, we have differences vs the group with HFpEF in the incidence of PCI in history - 58.8 vs 24.2% (χ2=5.752; P=0.017); eGFR
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2021.10.026